Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akari Therapeutics plc (AKTX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including current reports, registration statements, and proxy materials related to its oncology ADC platform. These documents are a primary source for understanding how Akari describes its PH1 spliceosome-modulating payload, lead ADC candidate AKTX-101, and broader corporate strategy.
Through Forms 8-K, Akari reports material events such as equity financings, warrant issuances, note offerings and exchanges, manufacturing partnerships, and leadership changes. Recent 8-K filings detail registered direct offerings and concurrent private placements, the terms of Series E, Series F, and Series G warrants, exchanges of unsecured promissory notes into equity-linked securities, and the company’s plans to use net proceeds for research and development, working capital, and general corporate purposes. Other 8-Ks describe Nasdaq minimum bid price deficiency notices and the company’s responses.
Akari’s registration statements, including shelf registrations and resale S-1 filings, outline the structure of its American Depositary Shares, the number of ordinary shares underlying various warrant series, and risk factor discussions related to its status as a development-stage oncology company without approved products or product revenue. These filings also summarize the company’s focus on developing ADCs with novel payloads and the role of its ADC discovery platform.
Proxy statements (DEF 14A) provide detail on shareholder meetings, resolutions related to share sub-division, warrant exercisability, authority to allot shares, and adoption of new articles of association. They also describe voting procedures for ordinary shareholders and ADS holders.
On Stock Titan, Akari’s SEC filings are updated in near real time from EDGAR and paired with AI-powered summaries that highlight key terms, capital structure changes, and regulatory milestones. Users can quickly scan 10-K or 20-F style risk discussions (when available), 10-Q or 6-K interim updates, and Form 4 insider transaction reports, then drill into the full text for deeper analysis of how financing, governance, and listing matters intersect with the company’s PH1-based ADC development plans.
Akari Therapeutics investor Ray Prudo has updated his ownership in a Schedule 13D/A Amendment No. 10. He is reported to beneficially own 8,391,326,467 ordinary shares, representing 8.9% of Akari’s ordinary shares, based on 91,567,009,533 shares outstanding as of March 1, 2026.
The filing reflects December 17, 2025 transactions where Dr. Prudo purchased Series G Warrants and Pre-Funded Warrants in a private placement and additional Note Exchange Warrants and Pre-Funded Warrants in a note cancellation and exchange, all at a combined price of $0.4041 per warrant pair, using personal funds.
Samir R. Patel reports beneficial ownership of 9,725,215,000 ordinary shares of Akari Therapeutics Plc, representing 10.4% of the company’s ordinary shares outstanding as of March 1, 2026. The shares are tied to Akari’s ordinary shares, which trade in ADS form on Nasdaq under the symbol AKTX.
The stake consists of 285,336,000 ordinary shares held directly by Dr. Patel, 6,062,010,000 shares held through PranaBio Investments LLC, 1,579,785,000 options exercisable within 60 days, and 1,798,084,000 shares underlying prefunded warrants exercisable within 60 days. Dr. Patel manages PranaBio and may be deemed the beneficial owner of its holdings.
The update reflects a December 17, 2025 private placement in which Dr. Patel bought Series G warrants, Note Exchange warrants, and prefunded warrants to purchase ADSs, all funded from his personal funds. Additional warrants for up to 5,450,454,000 shares are excluded because of a 9.99% beneficial ownership limitation.
Akari Therapeutics Plc amendment reports that Hoyoung Huh, M.D., Ph.D. beneficially owned 18,199,697,667 ordinary shares, representing 18.4% of the class based on
Akari Therapeutics, Plc reported results of a special general meeting where shareholders approved several warrant-related resolutions tied to prior financings and note exchanges. The meeting was held on March 2, 2026, with 91,567,009,533 ordinary shares entitled to vote, and all proposals passed.
Shareholders approved, for Nasdaq Listing Rule 5635(c) and 5635(d) purposes, the exercisability and related issuances for Series G Warrants and Placement Agent Warrants covering up to 10,043,774 and 504,300 American Depositary Shares, respectively. They also approved the exercisability of various Pre-Funded, Series G, and Note Exchange Warrants covering multiple blocks of ADSs issued in December 2025 transactions.
Akari Therapeutics, Plc is asking shareholders to approve the exercisability of several warrant issuances tied to recent financings and a note exchange. Five ordinary resolutions cover Series G Warrants, Pre-Funded Warrants, Note Exchange Warrants and Placement Agent Warrants issued in a registered direct offering, a concurrent private placement and a note exchange completed in December 2025 and January 2026.
The proposals would permit exercise of warrants for up to 10,043,774 ADSs plus 504,300 ADSs from placement agent warrants in the registered direct deal, 5,127,426 ADSs from the private placement, and 19,005,406 ADSs from the note exchange. If all Pre-Funded, Series G, Note Exchange and Placement Agent Warrants are exercised for cash, Akari states it could receive approximately $8.9 million in gross proceeds.
The board unanimously recommends voting in favor of each warrant exercise proposal and explains that without approval, the warrants cannot be exercised and the company would need to call additional shareholder meetings, adding cost. The proxy also explains detailed voting procedures for ordinary shareholders and ADS holders and outlines current major shareholdings.
Akari Therapeutics, Plc is registering up to 34,680,906 American Depositary Shares (ADSs), representing 69,361,812,000 ordinary shares, for resale by existing investors. These ADSs are issuable from a mix of Series G warrants, pre-funded warrants, note exchange warrants and placement agent warrants tied to Akari’s December 2025 registered direct and private offerings and a December 2025 note exchange. Akari is not selling shares itself and will not receive proceeds from investor resales, though it may receive up to $8.9 million if warrants are exercised for cash. As of January 22, 2026, Akari had 45,781,350 ADSs (91,562,700,000 ordinary shares) outstanding plus 4,309,533 ordinary shares not in ADS form. The company is repositioned as an oncology business focused on antibody-drug conjugates, led by preclinical candidate AKTX-101, and reports a long history of operating losses, limited cash (about $2.5 million at September 30, 2025), material weaknesses in internal controls, and significant ongoing capital needs, all highlighted in extensive risk factors.
Akari Therapeutics, Plc is asking shareholders at a March 2, 2026 general meeting to approve five resolutions that would allow the exercise of several series of warrants issued in recent financings and a note exchange, as required under Nasdaq Listing Rules 5635(c) and 5635(d). The warrants relate to a December 2025 registered direct offering of 10,043,774 ADSs with matching Series G Warrants, a concurrent private placement to directors and officers with 2,563,713 Pre-Funded Warrants and 2,563,713 Series G Warrants, and an exchange of about $4 million of 2026 notes into 9,502,703 Pre-Funded Warrants and 9,502,703 Note Exchange Warrants. The board unanimously recommends voting FOR all warrant exercise proposals. If all Pre-Funded, Series G, Note Exchange and Placement Agent Warrants are exercised, Akari states that 80,462,236 ADSs, representing 159,898,691,533 ordinary shares, would be outstanding and the company could receive about $8.9 million in cash proceeds.
Akari Therapeutics reported a set of concurrent equity-related transactions expected to reshape its financing. The company agreed to a registered direct offering and concurrent private placements of American Depositary Shares (ADSs) and warrants, with aggregate gross cash proceeds expected to be approximately $5 million. Investors will purchase 10,043,774 ADSs with accompanying Series G warrants, while certain directors and officers will purchase pre-funded warrants for 2,563,713 ADSs plus matching Series G warrants.
Separately, Akari entered into note exchange agreements to cancel approximately $4 million in principal of its 2026 unsecured promissory notes in return for new pre-funded and note exchange warrants, after which those notes will be retired at closing. The Series G and note exchange warrants have an exercise price of $0.3883 per ADS and generally become exercisable after shareholder approval, subject to 4.99%–9.99% beneficial ownership limits. The company plans to use net proceeds for continued research and development, working capital and general corporate purposes.
Akari Therapeutics, PLC is selling 10,043,774 American Depositary Shares (ADSs) in a registered direct offering at $0.3883 per ADS, raising $3,899,997 before fees.
The company expects net proceeds of approximately $3.3 million after placement agent fees and expenses, which it plans to use for continued research and development, working capital and other general corporate purposes. Akari expects to have 45,781,350 ADSs outstanding immediately after the offering, up from 35,767,576 ADSs outstanding before the deal, so new buyers face immediate dilution of approximately $0.65 per ADS.
Alongside the ADS sale, Akari is issuing an equal number of unregistered Series G warrants in a concurrent private placement, plus additional pre-funded and note exchange warrants to insiders and noteholders, all generally exercisable only after shareholder approval and subject to 4.99% or 9.99% ownership limits. Approximately $3.8 million principal amount of unsecured notes due 2026 will be exchanged into new equity-linked securities, and the company believes its cash, together with this financing, will fund operations into the second quarter of 2026.